BORTEZOMIB-MELPHALAN-PREDNISONE-THALIDOMIDE FOLLOWED BY BORTEZOMIB-THALIDOMIDE MAINTENANCE FOR INITIAL THERAPY OF MULTIPLE MYELOMA: A PROSPECTIVE RANDOMIZED TRIAL

被引：0
|
作者：
Palumbo, A. [1 ]
Bringhen, S. [1 ]
Rossi, D. [2 ]
Ria, R. [2 ]
Offidani, M. [2 ]
Musto, P. [2 ]
Petrucci, M. T. [2 ]
Omede, P. [1 ]
Di Raimondo, F. [2 ]
Boccadoro, M. [1 ]
机构：
[1] Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy
[2] Italian Multiple Myeloma Network, Gimema, Italy
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [21] Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
    Avvisati, Giuseppe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2613 - 2613
  • [22] Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Teruel, Ana-Isabel
    Bengoechea, Enrique
    Perez, Montse
    Lopez, Javier
    Diaz-Mediavilla, Joaquin
    Mariano Hernandez, Jose
    de Arriba, Felipe
    Gonzalez, Yolanda
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesas F.
    [J]. BLOOD, 2011, 118 (21) : 222 - 222
  • [23] Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
    Hjorth, Martin
    Hjertner, Oyvind
    Knudsen, Lene Meldgaard
    Gulbrandsen, Nina
    Holmberg, Erik
    Pedersen, Per Trollund
    Andersen, Niels Frost
    Andreasson, Bjorn
    Billstrom, Rolf
    Carlson, Kristina
    Carlsson, Margaretha S.
    Flogegard, Max
    Forsberg, Karin
    Gimsing, Peter
    Karlsson, Torbjorn
    Linder, Olle
    Nahi, Hareth
    Othzen, Annika
    Swedin, Agneta
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (06) : 485 - 496
  • [24] Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
    Shah, N.
    Weber, D.
    Orlowski, R.
    Wang, M.
    Thomas, S. K.
    Richards, T.
    Giralt, S.
    Qazilbash, M.
    Alexanian, R.
    Shah, J. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
    L Rosiñol
    A Oriol
    A I Teruel
    A L de la Guía
    MaJ Blanchard
    J de la Rubia
    M Granell
    MaA Sampol
    L Palomera
    Y González
    MaA Etxebeste
    R Martínez-Martínez
    M T Hernández
    F de Arriba
    A Alegre
    MaT Cibeira
    MaV Mateos
    J Martínez-López
    J J Lahuerta
    J San Miguel
    J Bladé
    [J]. Leukemia, 2017, 31 : 1922 - 1927
  • [26] Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
    Rosinol, L.
    Oriol, A.
    Teruel, A. I.
    de la Guia, A. L.
    Blanchard, Ma J.
    de la Rubia, J.
    Granell, M.
    Sampol, Ma A.
    Palomera, L.
    Gonzalez, Y.
    Etxebeste, Ma A.
    Martinez-Martinez, R.
    Hernandez, M. T.
    de Arriba, F.
    Alegre, A.
    Cibeira, Ma T.
    Mateos, Ma V.
    Martinez-Lopez, J.
    Lahuerta, J. J.
    Miguel, J. San
    Blade, J.
    [J]. LEUKEMIA, 2017, 31 (09) : 1922 - 1927
  • [27] Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly
    Mateos, M. V.
    Martin, M. L.
    Gonzalez, Y.
    Lahuerta, J. J.
    Blade, J.
    Oriol, A.
    Martinez, J.
    Cibeira, M. T.
    de Paz, R.
    Terol, M. J.
    Garcia, J.
    Bengoechea, E.
    Martinez, R.
    Martin, A.
    de Arriba, F.
    Palomera, L.
    Hernandez, J. M.
    Bello, J. L.
    San Miguel, J.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S25 - S25
  • [28] Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
    Zweegman, Sonja
    van der Holt, Bronno
    Mellqvist, Ulf-Henrik
    Salomo, Morten
    Bos, Gerard M. J.
    Levin, Mark-David
    Visser-Wisselaar, Heleen
    Hansson, Markus
    van der Velden, Annette W. G.
    Deenik, Wendy
    Gruber, Astrid
    Coenen, Juleon L. L. M.
    Plesner, Torben
    Klein, Saskia K.
    Tanis, Bea C.
    Szatkowski, Damian L.
    Brouwer, Rolf E.
    Westerman, Matthijs
    Leys, M. B. L.
    Sinnige, Harm A. M.
    Haukas, Einar
    van der Hem, Klaas G.
    Durian, Marc F.
    Mattijssen, E. J. M.
    van de Donk, Niels W. C. J.
    Stevens-Kroef, Marian J. P. L.
    Sonneveld, Pieter
    Waage, Anders
    [J]. BLOOD, 2016, 127 (09) : 1109 - 1116
  • [29] Oral melphalan, prednisone and thalidomide for multiple myeloma.
    Palumbo, A
    Bringhen, S
    Musto, P
    Caravita, T
    Capozzi, R
    Callea, V
    Cangialosi, C
    Montanaro, M
    Catalano, L
    Grasso, M
    Petti, MC
    Merla, M
    Falchi, L
    Omedè, P
    Ceccarelli, M
    Ambrosini, MT
    Avonto, I
    Gay, F
    Falco, P
    Boccadoro, M
    [J]. BLOOD, 2005, 106 (11) : 230A - 230A
  • [30] Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
    Kaufman, Jonathan L.
    Gleason, Charise
    Heffner, Leonard
    Lonial, Sagar
    [J]. BLOOD, 2007, 110 (11) : 1055A - 1055A
12345